### Vincristine

**Indication** | Diffuse large B-cell lymphomas  

**INN** | Vincristine  

**Medicine type** | Chemical agent  

**List type** | Complementary  

**Formulations** | Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)  

**EML status history** | First added in 2015 (TRS 994)  

| Changed in 2019 (TRS 1021)  

| Changed in 2021 (TRS 1035)  

**Sex** | All  

**Age** | Also recommended for children  

**Therapeutic alternatives** | The recommendation is for this specific medicine  

**Patent information** | Patents have expired in most jurisdictions  

**Read more about patents.**  

**Tags** | Cancer  

**Wikipedia** | Vincristine  

**DrugBank** | Vincristine  

### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.